This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Becker, Michael
| Item Type | Name |
|
Concept
|
Glucosephosphate Dehydrogenase
|
|
Concept
|
Glutathione Reductase
|
|
Concept
|
Glucosephosphate Dehydrogenase Deficiency
|
|
Concept
|
Xanthine Oxidase
|
|
Concept
|
Xanthine Dehydrogenase
|
|
Concept
|
Urate Oxidase
|
|
Academic Article
|
Update on emerging urate-lowering therapies.
|
|
Academic Article
|
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
|
|
Academic Article
|
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
|
|
Academic Article
|
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
|
|
Academic Article
|
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
|
|
Academic Article
|
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
|
|
Academic Article
|
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
|
|
Academic Article
|
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
|
|
Academic Article
|
Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
|
|
Academic Article
|
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
|
|
Academic Article
|
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
|
|
Academic Article
|
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
|
|
Academic Article
|
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
|
|
Academic Article
|
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
|
|
Academic Article
|
Genetic aspects of gout.
|
|
Academic Article
|
Regulation of 5-phosphoribosyl-1-pyrophosphate synthesis in human fibroblasts by the concentration of inorganic phosphate.
|
|
Academic Article
|
The phosphogluconate pathway and synthesis of 5-phosphoribosyl-1-pyrophosphate in human fibroblasts.
|